| Nesiritide in acute decompensated heart failure: a pooled analysis of randomized controlled trials. | |
| | |
MedLine Citation:
|
PMID: 20734445 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Previous randomized controlled trials (RCTs) evaluating nesiritide for the treatment of acute decompensated heart failure (ADHF) have reported wide variances in mortality hazard ratios for nesiritide vs controls, but these individual trials were neither designed nor powered to evaluate mortality. This study used relevant data from all RCTs of nesiritide in ADHF completed as of June 2006 to independently estimate the effect of nesiritide on 30- and 180-day mortality. HYPOTHESIS: Administration of nesiritide to treat patients with ADHF does not significantly increase mortality at 30 or 180 days. METHODS: Six trials met prespecified criteria for inclusion in this analysis. Primary data from these trials were obtained from Scios Inc. (Fremont, CA). Statistical models were fitted to estimate 4 effects: dose response, differing control groups, vulnerable subgroup interactions, and time of death relative to nesiritide administration. All models included 4 baseline covariates that were significantly and independently associated with mortality. RESULTS: Complete covariate data were available in 1472 of 1538 subjects (96%). The risk-adjusted hazard ratio for mortality was 1.05 (95% confidence interval [CI]: 0.85-1.30) at 30 and 1.00 (95% CI: 0.88-1.14) at 180 days with no clear relationship to nesiritide dose. In addition to consistent results across 2 time points, no significant evidence of sensitivity to control group or baseline risk factors was found. CONCLUSIONS: Currently available data suggest nesiritide does not significantly increase mortality at 30 or 180 days. |
| | |
Authors:
|
William T Abraham; Robin J Trupp; David Jarjoura |
Related Documents
:
|
8089035 - Analysis of single trial movement-related brain macropotential. 22115085 - Kinetic limitations on tracer partitioning in ganglia dominated source zones. 1588355 - Application of a stopping rule based on total treatment failures: the postoperative cro... 22553495 - Vascular development in the zebrafish. 21148415 - Virtualleaf: an open-source framework for cell-based modeling of plant tissue growth an... 1815055 - Area-based estimation of the initial volume of distribution and elimination rate consta... |
Publication Detail:
|
Type: Journal Article; Meta-Analysis |
Journal Detail:
|
Title: Clinical cardiology Volume: 33 ISSN: 1932-8737 ISO Abbreviation: Clin Cardiol Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-08-24 Completed Date: 2010-12-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7903272 Medline TA: Clin Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 484-9 Citation Subset: IM |
Affiliation:
|
Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA. william.abraham@osumc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Evidence-Based Medicine Heart Failure / drug therapy*, mortality Humans Natriuretic Agents / administration & dosage, adverse effects, therapeutic use* Natriuretic Peptide, Brain / administration & dosage, adverse effects, therapeutic use* Proportional Hazards Models Randomized Controlled Trials as Topic Risk Assessment Risk Factors Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Natriuretic Agents; 114471-18-0/Natriuretic Peptide, Brain |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Periprocedural myocardial infarction: review and classification.
Next Document: Efficacy of fractional flow reserve measurements at side branch vessels treated with the crush stent...